JHJnjm de Hoon

Jnjm de Hoon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jnjm de Hoon has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Karel Allegaert

    Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium, Leuven, Belgium; Department of Development and Regeneration, Catholic University of Leuven, Leuven, Belgium; Department of Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands, Belgium

    3 shared publications
  • J Troost

    Department of Neurology, University Hospital of Maastricht, Maastricht, The Netherlands

    2 shared publications
  • Aida Kulo

    Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina

    1 shared publication
  • Anne Debeer

    Neonatal Intensive Care Unit, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium

    1 shared publication
  • Anne Smits

    Department of Development and Regeneration, KU Leuven, Leuven, Belgium

    1 shared publication
  • C. Vanhole

    1 shared publication

Latest Publications

  • Open Access

    Biochemical tolerance during low dose propylene glycol exposure in neonates: A formulation-controlled evaluation

    by Aida Kulo, Anne Smits, Gunnar Naulaers, Jan de Hoon, Karel Allegaert

    Propylene glycol (PG) is a frequently co-administered solvent in formulations administered to neonates, but reports on its (in)tolerance are limited. We aimed to report on renal, metabolic and hepatic tolerance before, during and following intravenous (iv) PG-paracetamol exposure and compared these data with similar datasets reported in literature on neonates exposed to PG without paracetamol or paracetamol without PG. Renal (diuresis, creatinemia, sodium), metabolic (Base Excess, Anion Gap, lactate, bicarbonate) and hepatic (liver enzymes, bilirubinemia) indicators before, during and following iv paracetamol-PG exposure in neonates as included in the PARANEO (paracetamol in neonates) study (intra-individual trends, ANOVA) were collected and analysed. Comparison with observations collected in cases exposed to either iv phenobarbital-PG or iv paracetamol-mannitol (inter-individual comparison, Mann Whitney-U test) were made. PG exposure (median 34.1 mg/kg/24 h) did not affect postnatal renal, metabolic and hepatic adaptations in 60 cases exposed to paracetamol-PG. These indicators were similar when compared to 29 cases exposed to phenobarbital-PG or 172 cases exposed to paracetamol-mannitol. Based on observations in 89 neonates, low dose PG exposure was tolerated well. Studies on PG pharmacokinetics and its covariates are needed to estimate the upper level of PG tolerance in neonates.


  • Open Access

    Renal Side Effects of Non-Steroidal Anti-Inflammatory Drugs in Neonates

    by Karel Allegaert, Jan De Hoon, Anne Debeer, Marc Gewillig

    Non-steroidal anti-inflammatory drugs like ibuprofen or indomethacin are commonly prescribed drugs to induce pharmacologic closure of a patent ductus arteriosus in preterm neonates. Based on a recently published Cochrane meta-analysis, both drugs are equally effective to induce closure. Drug choice can therefore be based on differences in side effects or pharmaco-economic arguments. The current review quantifies the negative impact of either ibuprofen or indomethacin on renal function, including diuresis, glomerular filtration rate and renal tubular function. Both ibuprofen and indomethacin have a quantifiable impact on renal function. However, compared to ibuprofen, the negative impact of indomethacin is more pronounced.


  • Cefazolin plasma protein binding saturability during pregnancy

    by K. Allegaert, T. Van Mieghem, R. Verbesselt, C. Vanhole, R. Devlieger, V. Cossey, J. Deprest, J. de Hoon

    Get journal articles and books quickly, efficiently and at the lowest cost. Save up to 20% on article spend. Article Galaxy - Research Solutions/Reprints Desk.


  • Altered arterial function in migraine of recent onset

    by Floris H. Vanmolkot, Luc M. Van Bortel, Jan N. de Hoon

    Objective: Migraine is associated with cardiovascular disorders but the underlying mechanisms are unknown. Arterial structure and function are important determinants of cardiovascular morbidity and mortality. The aim of the present study was to assess arterial properties in patients with migraine of recent onset. Methods: In a cross-sectional study, structural and functional arterial properties were assessed using ultrasound and applanation tonometry in 50 patients with a history of migraine >1 and p = 0.01) and compliance (0.30 ± 0.17 mm2/kPa vs 0.37 ± 0.19 mm2/kPa, p = 0.02) were decreased in migraine patients compared with controls. Femoral artery compliance was decreased in migraine patients (1.19 ± 0.55 mm2/kPa vs 1.42 ± 0.59 mm2/kPa, p = 0.04). Carotid arterial wall properties were similar between groups. Aortic augmentation index was increased in migraine patients (4 ± 10% vs −1 ± 10%, adjusted p = 0.04). Flow-mediated vasodilation of the brachial artery (normalized to peak shear rate) was decreased in patients with migraine (29 ± 15 vs 37 ± 15 10−3%. sec, p = 0.006). Conclusion: Functional arterial properties are altered in patients with migraine of recent onset.


  • Forearm Vascular Response to Nitric Oxide and Calcitonin Gene- Related Peptide: Comparison between Migraine Patients and Control Subjects

    by Jnjm de Hoon, P Smits, J Troost, Haj Struijker-Boudier, Lmab Van Bortel

    The forearm vascular response to nitric oxide (NO) and calcitonin gene-related peptide (CGRP) was investigated in 10 migraine patients and 10 matched control subjects. Changes in forearm blood flow (FBF) during intrabrachial infusion of: (i) serotonin (releasing endogenous NO), (ii) sodium nitroprusside (SNP, exogenous NO-donor), and (iii) CGRP were measured using venous occlusion plethysmography. Flow-mediated dilation (FMD) of the brachial artery, a measure for the endogenous release of NO reactive to occlusion, was measured using ultrasound and expressed as percentage change vs. baseline diameter. FBF ratio (i.e. FBF in the infused over the control arm) at baseline (1.1 ± 0.1) did not differ between both populations. Serotonin, SNP and CGRP induced a dose-dependent increase ( P < 0.001) in FBF ratio in controls (to 2.8 ± 0.3, 6.7 ± 1.4 and 6.9 ± 1.2 at the highest dose, respectively) and migraineurs (2.5 ± 0.4, 5.6 ± 0.8 and 6.5 ± 1.3, respectively); these ratios did not differ between both groups. FMD was comparable in control subjects (5.8 ± 1%) and migraine patients (5.2 ± 1%). Based on the forearm vascular response to NO and CGRP, migraine patients do not display generalized changes in vascular function.


  • Calcitonin gene?related peptide: exploring its vasodilating mechanism of action in humans

    by J Dehoon, Peter Pickkers, Paul Smits, H Struijkerboudier, L Vanbortel

    In vitro studies suggest that the vasodilator mechanism of action of calcitonin gene-related peptide (CGRP) involves various endothelium-dependent and endothelium-independent mechanisms. An in vivo analysis of the contribution of nitric oxide, prostaglandins, calcium-sensitive potassium channels (K(+)(Ca) channels), and adenosine triphosphate (ATP)-sensitive potassium channels (K(+)(ATP) channels) to CGRP-induced vasodilation in humans was performed. CGRP (3, 10, and 30 ng x min(-1) x dL(-1) forearm) was infused into the brachial artery of 40 healthy subjects. Forearm vascular responses were measured by venous occlusion plethysmography. First, dose-response curves were constructed during coinfusion of CGRP with placebo (sodium chloride, 0.9%). After washout, in 5 subgroups (n = 8 each), the infusions of CGRP were repeated with placebo (time-control experiments), N(G)-monomethyl-L-arginine (L-NMMA, a nitric oxide-synthase inhibitor), indomethacin (a cyclooxygenase inhibitor), tetraethylammonium chloride (TEAC) (a K(+)(Ca)-channel blocker), and glyburide (INN, glibenclamide) (a K(+)(ATP)-channel blocker), respectively. CGRP induced a dose-dependent and reproducible decrease in forearm vascular resistance (P < .001). Compared with placebo, L-NMMA reduced the decrease in forearm vascular resistance induced by CGRP (P < .001) (3 and 10 ng x min(-1) x dL(-1) forearm). The absence of an inhibitory effect of L-NMMA on CGRP-induced vasodilation at the highest dose of CGRP suggests that still other mechanisms are involved. The vasodilator response to CGRP was not affected by coinfusion of indomethacin, tetraethylammonium chloride, or glyburide. The intrabrachial infusion of CGRP results in a dose-dependent and reproducible forearm vasodilator response. CGRP-induced vasodilation is dependent at least in part on the release of nitric oxide and does not involve the release of prostaglandins or the activation of K(+)(Ca) channels or K(+)(ATP) channels in humans.


  • Cranial and Peripheral Interictal Vascular Changes in Migraine Patients

    by Jn de Hoon, Jm Willigers, J Troost, Ha Struijker-Boudier, Lm Van Bortel

    As migraine is associated with an increased risk for ischaemic stroke and peripheral vasospastic disorders, it was hypothesized that interictal vascular changes may be present in migraine patients. Using ultrasound and applanation tonometry, the cardiovascular properties of migraine patients were compared with those of matched control subjects. Vascular parameters of the carotid arteries, cardiac output and systemic vascular resistance did not differ between both groups. Right temporal artery diameter was larger in migraine patients (mean difference 101 μm; 95% confidence interval (CI) 9/194 μm; P = 0.033). At the brachial artery, migraine patients displayed a smaller distension (difference -24 μm; 95% CI -45/-4 μm; P = 0.021) and a decreased compliance (difference -0.025 mm2/kPa; 95% CI -0.047/-0.003 mm2/kPa; P = 0.024). Thus, migraine patients display an increased peripheral arterial stiffness. The presence of these interictal vascular changes suggests that migraine might be part of a more generalized vascular disorder.


  • Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data

    by De Hoon, J. N. J. M.

    Aims To investigate the peripheral vascular effects and pharmacokinetics of dihydroergotamine (DHE) 0.5 mg after a single subcutaneous administration in humans. Methods A double-blind, placebo-controlled cross-over study was performed in 10 healthy male subjects. A wash-out period of 2 weeks separated the two study periods. During each period, just before and at regular intervals after drug administration, vascular measurements were performed and venous blood samples were drawn. Vessel wall properties were assessed at the brachial artery, by ultrasound and applanation tonometry. Blood pressure and heart rate were recorded with an oscillometric device. Forearm blood flow was measured with venous occlusion plethysmography. For all parameter-time curves the area under the curve (AUC) was calculated. Differences in AUC after placebo and DHE (ΔAUC) were analysed and the time-course of the difference assessed. DHE pharmacokinetics were analysed according to a two-compartment open model with an absorption phase. Results AUC for blood pressure, heart rate and forearm vascular resistance did not change after DHE. Brachial artery diameter and compliance decreased (P < 0.01); ΔAUC (95% confidence interval) equalled −8.81 mm h (−12.97/−4.65) and −0.98 mm2 kPa−1 h (−1.61/−0.34), respectively. Diameter decreased (P < 0.05) from 1 until 24 h after DHE (peak decrease 9.7% at 10 h); compliance from 2 until 32 h (24.8% at 2 h). Time to reach maximum plasma concentration of DHE averaged 0.33 ± 0.08 h (± s.e.mean); terminal half-life was 5.63 ± 1.15 h. Conclusions DHE decreased diameter and compliance of the brachial artery whereas forearm vascular resistance remained unchanged. Thus, DHE acts on conduit arteries without affecting resistance arteries. Furthermore, a discrepancy was demonstrated between the plasma concentrations of DHE which rapidly reach peak levels and quickly decline, and its long lasting vasoconstrictor activity.